News Center

Proxalutamide Phase III Clinical Trial for the Treatment of COVID-19 Patients Approved by FDA

Release time：2021-03-05 13:58

Suzhou, Mar.5, 2021--真人直营投注网站 (HKEX:9939) is pleased to announce that the Investigational New Drug (IND) application of the phase III clinical trial of Proxalutamide’s treatment of male COVID-19 outpatients has been approved by the United States Food and Drug Administration (FDA).

 

Kintor has been the first China-based biopharma company whose small-molecule novel drug was granted with a phase III clinical trial approval by the FDA for the treatment of COVID-19.

 

Dr. Tong Youzhi, the Founder, Chairman and CEO of Kintor Pharmaceutical, commented, “We are delighted to receive this phase III clinical trial approval from the FDA. This has been the first phase III clinical trial approval from the FDA since Kintor’s inception in 2009. We are driving at full force to execute clinical operations of this phase III clinical trial. According to the existing clinical data, the efficacy and safety profiles of Proxalutamide in the treatment of patients with COVID-19 are outstanding. We strive to launch Proxalutamide to the market for COVID-19 treatment as soon as possible, and help people around the globe to defeat COVID-19.”

Previous:

Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients

Next:

Completion of Patients’Recruitment for Proxalutamide’s COVID-19 Hospitalised Study

recommend News

Kintor